Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer could reveal hidden prostate cancer

NCT ID NCT04457232

Ongoing Diagnosis Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests a new imaging agent called 68Ga-FAPI-46, which targets a protein (FAP) found around tumor cells. Researchers want to see where this tracer goes in the body and whether it can highlight prostate cancer on PET scans. About 30 people with prostate cancer who are already scheduled for surgery or biopsy will receive the tracer and undergo imaging. The goal is to compare the scan results with tissue samples to see if the tracer accurately identifies cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a radioactive tracer called gallium Ga 68 FAPi-46
What this could lead to
If successful, this imaging method could help doctors better detect and understand prostate cancer, leading to more precise diagnosis and treatment planning.
What could go wrong
This is an early, small study focused on imaging, not treatment. The tracer may not reliably distinguish cancer from normal tissue, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE PROSTATE GLAND are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC MALIGNANT NEOPLASM IN THE PROSTATE GLAND PROSTATE CARCINOMA RECURRENT PROSTATE CARCINOMA

Contacts and locations

Locations

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.